nodes	percent_of_prediction	percent_of_DWPC	metapath
Brimonidine—Accidental exposure to product—Furosemide—dilated cardiomyopathy	0.114	0.152	CcSEcCtD
Brimonidine—Accidental ingestion—Furosemide—dilated cardiomyopathy	0.114	0.152	CcSEcCtD
Brimonidine—Unspecified visual loss—Lisinopril—dilated cardiomyopathy	0.0369	0.0491	CcSEcCtD
Brimonidine—Gastrointestinal symptom NOS—Spironolactone—dilated cardiomyopathy	0.0336	0.0447	CcSEcCtD
Brimonidine—Common cold—Lisinopril—dilated cardiomyopathy	0.0309	0.0411	CcSEcCtD
Brimonidine—Clonidine—SLC22A5—dilated cardiomyopathy	0.0204	1	CrCbGaD
Brimonidine—Lethargy—Spironolactone—dilated cardiomyopathy	0.0146	0.0195	CcSEcCtD
Brimonidine—Blindness—Lisinopril—dilated cardiomyopathy	0.0146	0.0194	CcSEcCtD
Brimonidine—ADRA2B—Adrenoceptors—ADRB1—dilated cardiomyopathy	0.0139	0.0607	CbGpPWpGaD
Brimonidine—ADRA2C—Adrenoceptors—ADRB1—dilated cardiomyopathy	0.0129	0.0567	CbGpPWpGaD
Brimonidine—ADRA2B—Adrenoceptors—ADRB2—dilated cardiomyopathy	0.0112	0.0492	CbGpPWpGaD
Brimonidine—Drowsiness—Spironolactone—dilated cardiomyopathy	0.011	0.0147	CcSEcCtD
Brimonidine—ADRA2A—Adrenoceptors—ADRB1—dilated cardiomyopathy	0.0105	0.0461	CbGpPWpGaD
Brimonidine—ADRA2C—Adrenoceptors—ADRB2—dilated cardiomyopathy	0.0105	0.046	CbGpPWpGaD
Brimonidine—Diabetes mellitus—Furosemide—dilated cardiomyopathy	0.00896	0.0119	CcSEcCtD
Brimonidine—Arthropathy—Lisinopril—dilated cardiomyopathy	0.00886	0.0118	CcSEcCtD
Brimonidine—Swelling—Furosemide—dilated cardiomyopathy	0.00884	0.0118	CcSEcCtD
Brimonidine—ADRA2A—Adrenoceptors—ADRB2—dilated cardiomyopathy	0.00852	0.0373	CbGpPWpGaD
Brimonidine—Lethargy—Furosemide—dilated cardiomyopathy	0.00796	0.0106	CcSEcCtD
Brimonidine—Photophobia—Lisinopril—dilated cardiomyopathy	0.00757	0.0101	CcSEcCtD
Brimonidine—Discomfort—Spironolactone—dilated cardiomyopathy	0.00726	0.00966	CcSEcCtD
Brimonidine—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.00673	0.00895	CcSEcCtD
Brimonidine—Nasal congestion—Lisinopril—dilated cardiomyopathy	0.00642	0.00855	CcSEcCtD
Brimonidine—Somnolence—Spironolactone—dilated cardiomyopathy	0.00626	0.00833	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00608	0.00809	CcSEcCtD
Brimonidine—Arthritis—Lisinopril—dilated cardiomyopathy	0.00602	0.00801	CcSEcCtD
Brimonidine—Drowsiness—Furosemide—dilated cardiomyopathy	0.00601	0.008	CcSEcCtD
Brimonidine—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.00585	0.00779	CcSEcCtD
Brimonidine—Face oedema—Lisinopril—dilated cardiomyopathy	0.00565	0.00752	CcSEcCtD
Brimonidine—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.00523	0.00696	CcSEcCtD
Brimonidine—Visual impairment—Furosemide—dilated cardiomyopathy	0.0052	0.00692	CcSEcCtD
Brimonidine—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00519	0.00691	CcSEcCtD
Brimonidine—Influenza—Lisinopril—dilated cardiomyopathy	0.00506	0.00673	CcSEcCtD
Brimonidine—Eye disorder—Furosemide—dilated cardiomyopathy	0.00504	0.00671	CcSEcCtD
Brimonidine—Pruritus—Spironolactone—dilated cardiomyopathy	0.00498	0.00663	CcSEcCtD
Brimonidine—ADRA2B—Monoamine GPCRs—ADRB1—dilated cardiomyopathy	0.0049	0.0215	CbGpPWpGaD
Brimonidine—Angiopathy—Furosemide—dilated cardiomyopathy	0.00489	0.00651	CcSEcCtD
Brimonidine—Immune system disorder—Furosemide—dilated cardiomyopathy	0.00487	0.00648	CcSEcCtD
Brimonidine—Bronchitis—Lisinopril—dilated cardiomyopathy	0.00486	0.00647	CcSEcCtD
Brimonidine—Arrhythmia—Furosemide—dilated cardiomyopathy	0.00482	0.00641	CcSEcCtD
Brimonidine—Erythema—Furosemide—dilated cardiomyopathy	0.0047	0.00625	CcSEcCtD
Brimonidine—Dizziness—Spironolactone—dilated cardiomyopathy	0.00466	0.0062	CcSEcCtD
Brimonidine—Dysgeusia—Furosemide—dilated cardiomyopathy	0.0046	0.00612	CcSEcCtD
Brimonidine—ADRA2C—Monoamine GPCRs—ADRB1—dilated cardiomyopathy	0.00458	0.0201	CbGpPWpGaD
Brimonidine—Depression—Lisinopril—dilated cardiomyopathy	0.0045	0.00598	CcSEcCtD
Brimonidine—Rash—Spironolactone—dilated cardiomyopathy	0.00444	0.00591	CcSEcCtD
Brimonidine—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00444	0.0059	CcSEcCtD
Brimonidine—Vision blurred—Furosemide—dilated cardiomyopathy	0.00443	0.00589	CcSEcCtD
Brimonidine—Headache—Spironolactone—dilated cardiomyopathy	0.00441	0.00587	CcSEcCtD
Brimonidine—Sinusitis—Lisinopril—dilated cardiomyopathy	0.00423	0.00563	CcSEcCtD
Brimonidine—Nausea—Spironolactone—dilated cardiomyopathy	0.00418	0.00557	CcSEcCtD
Brimonidine—Bradycardia—Lisinopril—dilated cardiomyopathy	0.00412	0.00548	CcSEcCtD
Brimonidine—ADRA2B—Amine ligand-binding receptors—ADRB1—dilated cardiomyopathy	0.00412	0.0181	CbGpPWpGaD
Brimonidine—Rhinitis—Lisinopril—dilated cardiomyopathy	0.00406	0.0054	CcSEcCtD
Brimonidine—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.00402	0.00535	CcSEcCtD
Brimonidine—ADRA2B—Monoamine GPCRs—ADRB2—dilated cardiomyopathy	0.00397	0.0174	CbGpPWpGaD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00397	0.00528	CcSEcCtD
Brimonidine—Dry mouth—Furosemide—dilated cardiomyopathy	0.00391	0.0052	CcSEcCtD
Brimonidine—ADRA2C—Amine ligand-binding receptors—ADRB1—dilated cardiomyopathy	0.00385	0.0169	CbGpPWpGaD
Brimonidine—Shock—Furosemide—dilated cardiomyopathy	0.00377	0.00502	CcSEcCtD
Brimonidine—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00376	0.005	CcSEcCtD
Brimonidine—Flushing—Lisinopril—dilated cardiomyopathy	0.00376	0.005	CcSEcCtD
Brimonidine—Skin disorder—Furosemide—dilated cardiomyopathy	0.00372	0.00495	CcSEcCtD
Brimonidine—ADRA2A—Monoamine GPCRs—ADRB1—dilated cardiomyopathy	0.00372	0.0163	CbGpPWpGaD
Brimonidine—ADRA2C—Monoamine GPCRs—ADRB2—dilated cardiomyopathy	0.00371	0.0163	CbGpPWpGaD
Brimonidine—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00367	0.00489	CcSEcCtD
Brimonidine—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00365	0.00485	CcSEcCtD
Brimonidine—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.00362	0.00481	CcSEcCtD
Brimonidine—Hypotension—Furosemide—dilated cardiomyopathy	0.00358	0.00477	CcSEcCtD
Brimonidine—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00355	0.00472	CcSEcCtD
Brimonidine—Erythema—Lisinopril—dilated cardiomyopathy	0.00352	0.00469	CcSEcCtD
Brimonidine—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.00345	0.00459	CcSEcCtD
Brimonidine—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00344	0.00458	CcSEcCtD
Brimonidine—Somnolence—Furosemide—dilated cardiomyopathy	0.00341	0.00453	CcSEcCtD
Brimonidine—ADRA2B—Amine ligand-binding receptors—ADRB2—dilated cardiomyopathy	0.00334	0.0146	CbGpPWpGaD
Brimonidine—Vision blurred—Lisinopril—dilated cardiomyopathy	0.00332	0.00442	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00331	0.0044	CcSEcCtD
Brimonidine—Fatigue—Furosemide—dilated cardiomyopathy	0.0033	0.0044	CcSEcCtD
Brimonidine—Pain—Furosemide—dilated cardiomyopathy	0.00328	0.00436	CcSEcCtD
Brimonidine—Syncope—Lisinopril—dilated cardiomyopathy	0.00316	0.0042	CcSEcCtD
Brimonidine—ADRA2A—Amine ligand-binding receptors—ADRB1—dilated cardiomyopathy	0.00313	0.0137	CbGpPWpGaD
Brimonidine—ADRA2C—Amine ligand-binding receptors—ADRB2—dilated cardiomyopathy	0.00312	0.0137	CbGpPWpGaD
Brimonidine—Palpitations—Lisinopril—dilated cardiomyopathy	0.00311	0.00414	CcSEcCtD
Brimonidine—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.0031	0.00412	CcSEcCtD
Brimonidine—Cough—Lisinopril—dilated cardiomyopathy	0.00307	0.00409	CcSEcCtD
Brimonidine—ADRA2A—Monoamine GPCRs—ADRB2—dilated cardiomyopathy	0.00301	0.0132	CbGpPWpGaD
Brimonidine—Arthralgia—Lisinopril—dilated cardiomyopathy	0.003	0.00399	CcSEcCtD
Brimonidine—Myalgia—Lisinopril—dilated cardiomyopathy	0.003	0.00399	CcSEcCtD
Brimonidine—Chest pain—Lisinopril—dilated cardiomyopathy	0.003	0.00399	CcSEcCtD
Brimonidine—Anxiety—Lisinopril—dilated cardiomyopathy	0.00299	0.00398	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00298	0.00396	CcSEcCtD
Brimonidine—Discomfort—Lisinopril—dilated cardiomyopathy	0.00296	0.00394	CcSEcCtD
Brimonidine—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00293	0.0039	CcSEcCtD
Brimonidine—Oedema—Lisinopril—dilated cardiomyopathy	0.00288	0.00383	CcSEcCtD
Brimonidine—Infection—Lisinopril—dilated cardiomyopathy	0.00286	0.0038	CcSEcCtD
Brimonidine—Shock—Lisinopril—dilated cardiomyopathy	0.00283	0.00376	CcSEcCtD
Brimonidine—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00282	0.00376	CcSEcCtD
Brimonidine—Tachycardia—Lisinopril—dilated cardiomyopathy	0.00281	0.00373	CcSEcCtD
Brimonidine—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00279	0.00372	CcSEcCtD
Brimonidine—Asthenia—Furosemide—dilated cardiomyopathy	0.00275	0.00366	CcSEcCtD
Brimonidine—Pruritus—Furosemide—dilated cardiomyopathy	0.00271	0.00361	CcSEcCtD
Brimonidine—Hypotension—Lisinopril—dilated cardiomyopathy	0.00269	0.00358	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00262	0.00349	CcSEcCtD
Brimonidine—Insomnia—Lisinopril—dilated cardiomyopathy	0.0026	0.00346	CcSEcCtD
Brimonidine—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00258	0.00344	CcSEcCtD
Brimonidine—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00256	0.00341	CcSEcCtD
Brimonidine—Somnolence—Lisinopril—dilated cardiomyopathy	0.00256	0.0034	CcSEcCtD
Brimonidine—Dizziness—Furosemide—dilated cardiomyopathy	0.00253	0.00337	CcSEcCtD
Brimonidine—ADRA2A—Amine ligand-binding receptors—ADRB2—dilated cardiomyopathy	0.00253	0.0111	CbGpPWpGaD
Brimonidine—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.00253	0.00337	CcSEcCtD
Brimonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.0025	0.011	CbGpPWpGaD
Brimonidine—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00248	0.0033	CcSEcCtD
Brimonidine—Fatigue—Lisinopril—dilated cardiomyopathy	0.00248	0.0033	CcSEcCtD
Brimonidine—Pain—Lisinopril—dilated cardiomyopathy	0.00246	0.00327	CcSEcCtD
Brimonidine—Rash—Furosemide—dilated cardiomyopathy	0.00242	0.00322	CcSEcCtD
Brimonidine—Dermatitis—Furosemide—dilated cardiomyopathy	0.00241	0.00321	CcSEcCtD
Brimonidine—Headache—Furosemide—dilated cardiomyopathy	0.0024	0.00319	CcSEcCtD
Brimonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.00234	0.0102	CbGpPWpGaD
Brimonidine—Nausea—Furosemide—dilated cardiomyopathy	0.00228	0.00303	CcSEcCtD
Brimonidine—ADRA2B—Platelet activation, signaling and aggregation—TTN—dilated cardiomyopathy	0.00226	0.00992	CbGpPWpGaD
Brimonidine—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00212	0.00282	CcSEcCtD
Brimonidine—ADRA2C—Platelet activation, signaling and aggregation—TTN—dilated cardiomyopathy	0.00211	0.00927	CbGpPWpGaD
Brimonidine—Asthenia—Lisinopril—dilated cardiomyopathy	0.00206	0.00275	CcSEcCtD
Brimonidine—Pruritus—Lisinopril—dilated cardiomyopathy	0.00203	0.00271	CcSEcCtD
Brimonidine—ADRA2B—Platelet activation, signaling and aggregation—ACTN2—dilated cardiomyopathy	0.00196	0.0086	CbGpPWpGaD
Brimonidine—Dizziness—Lisinopril—dilated cardiomyopathy	0.0019	0.00253	CcSEcCtD
Brimonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.0019	0.00832	CbGpPWpGaD
Brimonidine—ADRA2C—Platelet activation, signaling and aggregation—ACTN2—dilated cardiomyopathy	0.00183	0.00803	CbGpPWpGaD
Brimonidine—Rash—Lisinopril—dilated cardiomyopathy	0.00181	0.00241	CcSEcCtD
Brimonidine—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00181	0.00241	CcSEcCtD
Brimonidine—Headache—Lisinopril—dilated cardiomyopathy	0.0018	0.0024	CcSEcCtD
Brimonidine—ADRA2A—Platelet activation, signaling and aggregation—TTN—dilated cardiomyopathy	0.00172	0.00753	CbGpPWpGaD
Brimonidine—Nausea—Lisinopril—dilated cardiomyopathy	0.00171	0.00227	CcSEcCtD
Brimonidine—ADRA2B—Platelet activation, signaling and aggregation—VCL—dilated cardiomyopathy	0.00167	0.00731	CbGpPWpGaD
Brimonidine—ADRA2C—Platelet activation, signaling and aggregation—VCL—dilated cardiomyopathy	0.00156	0.00683	CbGpPWpGaD
Brimonidine—ADRA2A—Platelet activation, signaling and aggregation—ACTN2—dilated cardiomyopathy	0.00149	0.00652	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—ANKRD1—dilated cardiomyopathy	0.00142	0.00623	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—TAZ—dilated cardiomyopathy	0.00134	0.00586	CbGpPWpGaD
Brimonidine—ADRA2A—Platelet activation, signaling and aggregation—VCL—dilated cardiomyopathy	0.00127	0.00555	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—SDHA—dilated cardiomyopathy	0.00121	0.0053	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—TTN—dilated cardiomyopathy	0.00117	0.00511	CbGpPWpGaD
Brimonidine—ADRA2B—G alpha (i) signalling events—CXCL2—dilated cardiomyopathy	0.00113	0.00496	CbGpPWpGaD
Brimonidine—ADRA2B—G alpha (i) signalling events—AGTR2—dilated cardiomyopathy	0.00113	0.00496	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—TTN—dilated cardiomyopathy	0.00109	0.00478	CbGpPWpGaD
Brimonidine—ADRA2C—G alpha (i) signalling events—CXCL2—dilated cardiomyopathy	0.00106	0.00463	CbGpPWpGaD
Brimonidine—ADRA2C—G alpha (i) signalling events—AGTR2—dilated cardiomyopathy	0.00106	0.00463	CbGpPWpGaD
Brimonidine—ADRA2B—G alpha (i) signalling events—CXCR3—dilated cardiomyopathy	0.00105	0.00461	CbGpPWpGaD
Brimonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.00105	0.0046	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—ACTN2—dilated cardiomyopathy	0.00101	0.00443	CbGpPWpGaD
Brimonidine—ADRA2C—G alpha (i) signalling events—CXCR3—dilated cardiomyopathy	0.000983	0.00431	CbGpPWpGaD
Brimonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000981	0.0043	CbGpPWpGaD
Brimonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000976	0.00428	CbGpPWpGaD
Brimonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000946	0.00414	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—ACTN2—dilated cardiomyopathy	0.000945	0.00414	CbGpPWpGaD
Brimonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000912	0.004	CbGpPWpGaD
Brimonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.0009	0.00394	CbGpPWpGaD
Brimonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.0009	0.00394	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—TTN—dilated cardiomyopathy	0.000885	0.00388	CbGpPWpGaD
Brimonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000883	0.00387	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—VCL—dilated cardiomyopathy	0.00086	0.00377	CbGpPWpGaD
Brimonidine—ADRA2A—G alpha (i) signalling events—CXCL2—dilated cardiomyopathy	0.000859	0.00376	CbGpPWpGaD
Brimonidine—ADRA2A—G alpha (i) signalling events—AGTR2—dilated cardiomyopathy	0.000859	0.00376	CbGpPWpGaD
Brimonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000841	0.00368	CbGpPWpGaD
Brimonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000841	0.00368	CbGpPWpGaD
Brimonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000837	0.00367	CbGpPWpGaD
Brimonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.00081	0.00355	CbGpPWpGaD
Brimonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000808	0.00354	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—VCL—dilated cardiomyopathy	0.000803	0.00352	CbGpPWpGaD
Brimonidine—ADRA2A—G alpha (i) signalling events—CXCR3—dilated cardiomyopathy	0.000798	0.0035	CbGpPWpGaD
Brimonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000797	0.00349	CbGpPWpGaD
Brimonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000781	0.00343	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—ACTN2—dilated cardiomyopathy	0.000767	0.00336	CbGpPWpGaD
Brimonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000766	0.00336	CbGpPWpGaD
Brimonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000757	0.00332	CbGpPWpGaD
Brimonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000754	0.00331	CbGpPWpGaD
Brimonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000741	0.00325	CbGpPWpGaD
Brimonidine—AOX1—Disease—NPPA—dilated cardiomyopathy	0.000739	0.00324	CbGpPWpGaD
Brimonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000717	0.00314	CbGpPWpGaD
Brimonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000716	0.00314	CbGpPWpGaD
Brimonidine—AOX1—Disease—PSEN2—dilated cardiomyopathy	0.000716	0.00314	CbGpPWpGaD
Brimonidine—ADRA2B—Platelet activation, signaling and aggregation—CD36—dilated cardiomyopathy	0.000714	0.00313	CbGpPWpGaD
Brimonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000692	0.00303	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000685	0.003	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000685	0.003	CbGpPWpGaD
Brimonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000683	0.00299	CbGpPWpGaD
Brimonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000683	0.00299	CbGpPWpGaD
Brimonidine—ADRA2B—Platelet activation, signaling and aggregation—RAC1—dilated cardiomyopathy	0.000673	0.00295	CbGpPWpGaD
Brimonidine—ADRA2C—Platelet activation, signaling and aggregation—CD36—dilated cardiomyopathy	0.000667	0.00293	CbGpPWpGaD
Brimonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000656	0.00288	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—VCL—dilated cardiomyopathy	0.000652	0.00286	CbGpPWpGaD
Brimonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000646	0.00283	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.00064	0.00281	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.00064	0.00281	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000637	0.00279	CbGpPWpGaD
Brimonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000635	0.00278	CbGpPWpGaD
Brimonidine—ADRA2C—Platelet activation, signaling and aggregation—RAC1—dilated cardiomyopathy	0.000629	0.00276	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—ANKRD1—dilated cardiomyopathy	0.00062	0.00272	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000617	0.0027	CbGpPWpGaD
Brimonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000615	0.00269	CbGpPWpGaD
Brimonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000613	0.00269	CbGpPWpGaD
Brimonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000613	0.00269	CbGpPWpGaD
Brimonidine—ADRA2B—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.000612	0.00268	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000595	0.00261	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—TAZ—dilated cardiomyopathy	0.000583	0.00255	CbGpPWpGaD
Brimonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000581	0.00255	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000576	0.00253	CbGpPWpGaD
Brimonidine—ADRA2C—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.000572	0.00251	CbGpPWpGaD
Brimonidine—ADRA2A—Platelet activation, signaling and aggregation—CD36—dilated cardiomyopathy	0.000542	0.00238	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—SDHA—dilated cardiomyopathy	0.000527	0.00231	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000527	0.00231	CbGpPWpGaD
Brimonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000525	0.0023	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.00052	0.00228	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.00052	0.00228	CbGpPWpGaD
Brimonidine—ADRA2A—Platelet activation, signaling and aggregation—RAC1—dilated cardiomyopathy	0.000511	0.00224	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ANKRD1—dilated cardiomyopathy	0.000504	0.00221	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.0005	0.00219	CbGpPWpGaD
Brimonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000498	0.00218	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000492	0.00216	CbGpPWpGaD
Brimonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000487	0.00213	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000483	0.00212	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—TAZ—dilated cardiomyopathy	0.000473	0.00208	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000468	0.00205	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000467	0.00205	CbGpPWpGaD
Brimonidine—ADRA2A—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.000465	0.00204	CbGpPWpGaD
Brimonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000455	0.00199	CbGpPWpGaD
Brimonidine—ADRA2B—Platelet activation, signaling and aggregation—RAF1—dilated cardiomyopathy	0.000446	0.00196	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—ITGB1—dilated cardiomyopathy	0.000432	0.00189	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—SDHA—dilated cardiomyopathy	0.000428	0.00188	CbGpPWpGaD
Brimonidine—ADRA2C—Platelet activation, signaling and aggregation—RAF1—dilated cardiomyopathy	0.000417	0.00183	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—ITGB1—dilated cardiomyopathy	0.000403	0.00177	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.0004	0.00175	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000387	0.0017	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000387	0.0017	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000379	0.00166	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000371	0.00163	CbGpPWpGaD
Brimonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000369	0.00162	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—CD36—dilated cardiomyopathy	0.000368	0.00161	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000362	0.00159	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000362	0.00159	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.00036	0.00158	CbGpPWpGaD
Brimonidine—AOX1—Disease—RAC1—dilated cardiomyopathy	0.00036	0.00158	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000352	0.00154	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000352	0.00154	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000349	0.00153	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—RAC1—dilated cardiomyopathy	0.000347	0.00152	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000346	0.00152	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—CD36—dilated cardiomyopathy	0.000344	0.00151	CbGpPWpGaD
Brimonidine—ADRA2A—Platelet activation, signaling and aggregation—RAF1—dilated cardiomyopathy	0.000339	0.00148	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000336	0.00147	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000328	0.00144	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000328	0.00144	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—GPX1—dilated cardiomyopathy	0.000328	0.00144	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—ITGB1—dilated cardiomyopathy	0.000328	0.00144	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000327	0.00143	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000326	0.00143	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—RAC1—dilated cardiomyopathy	0.000324	0.00142	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—CD36—dilated cardiomyopathy	0.00032	0.0014	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000317	0.00139	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000305	0.00134	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000298	0.00131	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000296	0.0013	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000294	0.00129	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000294	0.00129	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—AGT—dilated cardiomyopathy	0.000288	0.00126	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000282	0.00124	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000281	0.00123	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—CD36—dilated cardiomyopathy	0.000279	0.00122	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000278	0.00122	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000273	0.0012	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.00027	0.00119	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000267	0.00117	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000267	0.00117	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000265	0.00116	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000264	0.00116	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—RAC1—dilated cardiomyopathy	0.000263	0.00115	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000257	0.00112	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000253	0.00111	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000248	0.00109	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.00024	0.00105	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.00024	0.00105	CbGpPWpGaD
Brimonidine—AOX1—Disease—RAF1—dilated cardiomyopathy	0.000239	0.00105	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000234	0.00103	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—RAF1—dilated cardiomyopathy	0.00023	0.00101	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000226	0.00099	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000219	0.000961	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000219	0.000958	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—RAF1—dilated cardiomyopathy	0.000215	0.000942	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000214	0.000939	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.00021	0.000918	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000208	0.000911	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000208	0.000911	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000205	0.000899	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000205	0.000898	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000199	0.000873	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000196	0.000858	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000195	0.000853	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000194	0.000851	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000194	0.000851	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000193	0.000846	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—AGT—dilated cardiomyopathy	0.00019	0.000834	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000187	0.00082	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000186	0.000815	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.00018	0.000791	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000178	0.000779	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000178	0.000778	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000175	0.000766	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—RAF1—dilated cardiomyopathy	0.000175	0.000765	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000166	0.000729	CbGpPWpGaD
Brimonidine—AOX1—Disease—EGFR—dilated cardiomyopathy	0.000164	0.000717	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.00016	0.0007	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000159	0.000697	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000158	0.000691	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000158	0.000691	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000152	0.000664	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000151	0.000662	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000149	0.000654	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000147	0.000642	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000144	0.000633	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—GPX1—dilated cardiomyopathy	0.000143	0.000628	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000142	0.000622	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000142	0.00062	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—CD36—dilated cardiomyopathy	0.000139	0.000611	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000132	0.000579	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.00013	0.000571	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—AGT—dilated cardiomyopathy	0.000126	0.00055	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000123	0.000541	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000122	0.000533	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000121	0.000531	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000118	0.000516	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—GPX1—dilated cardiomyopathy	0.000116	0.00051	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000115	0.000504	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CD36—dilated cardiomyopathy	0.000113	0.000497	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—AGT—dilated cardiomyopathy	0.000112	0.000493	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—RAC1—dilated cardiomyopathy	0.00011	0.000482	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—AGT—dilated cardiomyopathy	0.000105	0.00046	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—AGT—dilated cardiomyopathy	0.000102	0.000447	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.0001	0.000439	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	9.88e-05	0.000433	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—EGFR—dilated cardiomyopathy	9.06e-05	0.000397	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—RAC1—dilated cardiomyopathy	8.93e-05	0.000391	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—AGT—dilated cardiomyopathy	8.53e-05	0.000374	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—EGFR—dilated cardiomyopathy	8.46e-05	0.000371	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—RAF1—dilated cardiomyopathy	7.8e-05	0.000342	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—RAF1—dilated cardiomyopathy	7.29e-05	0.000319	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—EGFR—dilated cardiomyopathy	6.87e-05	0.000301	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—RAF1—dilated cardiomyopathy	5.92e-05	0.000259	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—EGFR—dilated cardiomyopathy	5.35e-05	0.000234	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—EGFR—dilated cardiomyopathy	5e-05	0.000219	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—EGFR—dilated cardiomyopathy	4.06e-05	0.000178	CbGpPWpGaD
